Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection.

abstract CC BY

BackgroundThe systemic immune-inflammation index based on peripheral neutrophil, lymphocyte, and platelet counts has shown a prognostic impact in several malignancies. The aim of this study was to determine the prognostic role of systemic immune-inflammation index in patients with pancreatic ductal adenocarcinoma undergoing resection.MethodsConsecutive patients who underwent surgical resection at the department of surgery at the Medical University of Vienna between 1995 and 2014 were included into this study. The systemic immune-inflammation index was calculated by the formula platelet*neutrophil/lymphocyte. Optimal cutoffs were determined using Youden’s index. Uni- and multivariate analyses were calculated by the Cox proportional hazard regression model for overall survival.ResultsThree hundred twenty-one patients were included in this study. Clinical data was achieved from a prospective patient database. In univariate survival analysis, elevated systemic immune-inflammation index was found to be significantly associated with shortened patients’ overall survival (p = 0.007). In multivariate survival analysis, systemic immune-inflammation index remained an independent prognostic factor for overall survival (p = 0.004). No statistical significance could be found for platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in multivariate analysis. Furthermore, area under the curve analysis showed a higher prognostic significance for systemic immune-inflammation index, compared to platelet to lymphocyte ratio and neutrophil to lymphocyte ratio.ConclusionA high systemic immune-inflammation index is an independent, preoperative available prognostic factor in patients with resectable pancreatic ductal adenocarcinoma and is superior to platelet to lymphocyte ratio and neutrophil to lymphocyte ratio for predicting overall survival in pancreatic ductal adenocarcinoma patients.

introduction CC BY

Pancreatic ductal adenocarcinoma (PDAC) is the ninth most common malignancy and ranks fifth place of cancer-related death in western countries with inclining incidence.1 Despite the development of multimodal approaches, combining surgical resection with perioperative chemo-(radio)therapy, 5-year survival rate for patients diagnosed with PADC remains poor with less than 5%.2 Inflammation, as one of the hallmarks of cancer, is an acknowledged factor in tumor biology.3,4 Inflammation-driven tumorigenesis and tumor progression plays a crucial role in malignant diseases.3,5 Systemic inflammatory response (SIR) in the context of tumor-associated inflammation has been demonstrated to diminish outcome and be of major prognostic importance in various cancers.6,7 A number of promising and potentially prognostic immunologic and histologic biomarkers have been investigated in PDAC.8,9 However, evaluation of these biomarkers is often expensive and time-consuming. Thus, investigation of tumor-driving inflammation-based components is of major importance and targeting pathways of inflammatory response might become a cornerstone of cancer treatment.10 In PDAC, outcome prediction mainly depends on clinical and pathological factors, such as tumor size, lymph node involvement, and distant metastases as well as resection margin.11 Notably, these factors are obtained post-operatively through evaluation of the surgical specimen and current available prognostic markers do not allow to preoperatively predict outcome. Therefore, identification of easy-available markers might help to determine individual treatment approaches. The utility of inflammation-based scores, such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII), are based on routinely obtained markers that are available before surgery. Elevated SII has been reported to be associated with clinico-pathological parameters and has been proven to be an independent prognostic factor in a number of malignancies, including PDAC.12–16 However, no data exists until now, describing the prognostic value of the SII in PDAC after neoadjuvant treatment. The aim of the present study was to assess the prognostic value of SII in patients undergoing a potentially curative resection for PDAC with or without neoadjuvant therapy. Furthermore, the SII is compared with NLR and PLR in predicting survival in this cohort of patients.

material and methods CC BY

Patients undergoing resection for PDAC between 1995 and 2014 at the Department of Surgery, Medical University of Vienna, were identified from a prospectively maintained PDAC database. Both patients who primarily underwent surgery and patients with borderline resectable disease according to NCCN guidelines who were treated by chemotherapy or radio-chemotherapy before resection were included.17 The study was approved by the Ethics Committee of the Medical University Vienna, Austria, in accordance with the Helsinki declaration (EK 1166/2013). Clinico-pathological data were assembled from medical records, including, gender, age, preoperative neutrophil, lymphocyte and platelet counts, tumor site, histopathological tumor grading, staging (TNM) according to the 8th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC), neoadjuvant treatment and surgical resection technique. Tumor resection margin status (R) was classified as R0 or R1 (1-mm tumor-free margin). Patients with distant metastases at time of diagnosis and death from other cause within 30 days post-surgery as well as patients who had recently pyrexia (axillary ≥ 37.2 °C/99.0 °F), any form of active infection or chronic inflammatory disease were excluded from the study. Each patient was discussed in the multidisciplinary team meeting before surgery. Neo-/adjuvant chemotherapy was administered according to the standard regimens available at the respective period. For neoadjuvant treatment, 5-fluorouracil was used from 1995 to 1998, whereas gemcitabine-based regimens (gemcitabine monotherapy and combinations with oxaliplatin, erlotinib, and nab-Paclitaxel) or FOLFIRINOX were used from 1999 onwards. The present standard for neoadjuvant treatment since several years consists of either FOLFIRINOX or Gem/nab-Pac depending on patients’ condition. For adjuvant chemotherapy, 5-fluorouracil-based regimens were used between 1995 and 1998 and gemcitabine-based regimens were administered thereafter. All patients were regularly followed thereafter with physical examination, tumor marker, and computed tomographic scan every 3 months for the first 2 years and every 6 months until 5 years after surgery. Blood samples were obtained within 7 days prior to surgery. NLR, PLR, and SII were calculated as previously described: NLR = neutrophils / lymphocytes, PLR = platelet / lymphocytes, and SII = platelets × neutrophils / lymphocytes.16

statistical analysis CC BY

Statistical analysis was performed using the R statistical software (Version 3.4.3) with the “Survival,” “pROC,” and “Optimal Cutpoints” packages.18–21 To evaluate the discriminatory ability of the SII, NLR, and PLR, ROC curves were generated and the area under the ROC curves (AUROCs) was measured and compared. For bivariate analysis, to investigate relationships between SII, NLR, and PLR and clinico-pathological parameters, t test and the Wilcoxon test were used as appropriate. Univariate and multivariate analyses were conducted using the Cox proportional hazard model. In the multivariable model, SII, NLR, and PLR could not be included into together, due to multicollinearity. Therefore, the stepwise regression analysis for multivariate Cox models, SII, NLR, and PLR could not be included into the model together due to multicollinearity. Discrimination ability was compared using the receiver operating curve. Optimal cutoff values for SII, NLR, and PLR were determined using Youden’s index, which maximizes the sum of sensitivity and specificity. Graphically, it is represented by the distance between the 45-degree line and the ROC22,23. The graphical analysis was performed using the Kaplan-Meier survival curve estimator and analyzed by the log-rank test. Overall survival (OS) was defined as time between primary surgery and the patients’ death. Death from other cause than PDAC or survival until the end of the observation period was considered as censored observations. Disease-free survival (DFS) was defined from the day of surgery until first evidence of disease progression. Categorical data was analyzed using the chi-squared test. Continuous data was either analyzed using the t test form normally distributed values or the Wilcoxon rank-sum test.

results CC BY

In the present study, a total of 321 patients (169, 52.2% male) with a median age of 68.5 (range, 35.9–92.3) years were included. The majority of patients (201, 62.6%) presented with a moderately differentiated tumor (G2) and 43 (13.3%) patients received neoadjuvant treatment prior to resection. In 255 (78.7%) cases, the tumor was located in the head of the pancreas and in 238 (73.5%) positive lymph node was found at pathological assessment. In accordance with the 8th edition UICC/AJCC classification, 265 (82.6%) patients showed stage II disease and 153 (47.2%) patients underwent biliary drainage preoperatively. Clinico-pathological data are presented in Table 1.Table 1Association of the SII with clinico-pathological parameters in pancreatic ductal adenocarcinomaFactorsAllSIIHigh (≥ 873)Low (< 873)p valuen324120204Age, mean (SD)68.25(9.74)68.81 (9.21)67.91 (10.04)> 0.1(*)Sex> 0.1 Male16952.16%65104 Female15547.84%55100(y)pT> 0.1 020.62%11 1247.41%519 24714.51%1829 323472.22%87147 4175.25%98(y)pN> 0.1 08626.54%2759 123873.46%93145(y)G> 0.1 1154.63%411 220462.96%72132 310532.41%4461R0.027 025478.40%86168 17021.60%3436UICC staging> 0.1 I4112.65%1526 II26581.79%96169 III185.56%108Neoadjuvant treatment> 0.1 yes4313.27%1429 no28186.73%106175Jaundice0.041 No16350.31%51112 Yes16149.69%6992CA 19-90.013 Unknown247.41%915 ≤ 114 kU/L14344.14%42101 > 114 kU/L15748.46%6988Lymph node-ratio> 0.1 Unknown237.10%716 ≤ 0.219660.49%71125 > 0.210532.41%4263Nicotine> 0.1 Unknown30.93%12 Yes13541.67%5580 No18657.41%64122Pain> 0.1 Yes13040.12%4585 No19459.88%75119Pancreatitis> 0.1 Yes6319.44%2043 No26180.56%100161Diabetes> 0.1 Unknown123.70%39 Yes7322.53%2944 No23973.77%88151Stent> 0.1 Yes15347.22%6093 No17152.78%60111Surgical procedure0.0345 PPPD18155.86%65116 Whipple7121.91%3536 Distal resection6018.52%1545 Total pancreatectomy123.70%57Localization> 0.1 125578.70%100155 2247.41%816 34513.89%1233(*) Using t testSD, standard deviation; UICC, Union for International Cancer Control; SII, systemic immune-inflammation index The median OS was 18.5 months (range, 1.5–198 months) and the rate of 3- and 5-year OS was 25.63% and 8.44%, respectively. The optimal cutoff values for SII, PLR, and NLR were 873, 179, and 225, respectively. With the defined cutoffs, 119 patients had SII ≥ 873, 125 patients had PLR ≥ 179, and 225 patients NLR ≥ 2.15 before surgery. Using bivariate analysis, significant relationship between elevated SII and clinico-pathological parameters was found for resection margin (p = 0.03), jaundice (p = 0.04), CA 19–9 (p = 0.01), and surgical procedure (p = 0.04) (Table 1). The median OS for patients with high SII was 14.2 (range, 1.5–128.2) months and 20.5 (range, 1.6–200.8) months for patients with low SII respectively. In the entire cohort, using overall survival as an end-point, the area under the receiver operator curve was 0.46 (CI, 0.37–0.55) for SII, 0.46 (CI, 0.36–0.56) for NLR, and 0.51 (CI, 0.42–0.61) for PLR with no significant difference in discrimination ability between SII, NLR, and PLR regarding OS was found (Fig. 1).Fig. 1Receiver operating characteristic (ROC) curves were generated to evaluate the discriminatory ability of the SII (a), NLR (b), and PLR (c). The area under the ROC curves (AUROCs) were measured and compared Kaplan-Meier curve survival analysis for all patients revealed that low SII (p = 0.004) and PLR (p = 0.04) were significantly associated with longer OS, whereas no significance was found for NLR (Fig. 2).Fig. 2Kaplan-Meier curves for overall survival (OS) stratified by SII (a), NLR (b) and PLR (c) Univariate Cox proportional hazard regression revealed that SII, PLR, age, jaundice, resection margin, CA 19-9, lymph node-ratio, and tumor size were significantly associated with OS. Similarly, age, jaundice, lymph node-ratio, and tumor size are significantly associated with DFS whereas SII, NLR, and PLR was not (Table 2).Table 2Univariate Cox regression analysis estimating the influence of the SII, NLR, PLR and clinico-pathological parameters on overall survival and disease-free survival in patients with ductal adenocarcinoma of the pancreasOverall survivalDisease-free survivalRRCI (95%)p valueRRCI (95%)p valueSII ≥ 873 vs. < 8730.69790.5469–0.89070.00380.81470.6288–1.05560.1211NLR ≥ 2.15 vs. < 2.150.78520.6054–1.01840.06830.85360.6455–1.12860.2666PLR ≥ 179 vs. < 1790.7720.6031–0.98820.03990.8080.6205–1.05220.1136UICC stage II vs. I1.06680.7438–1.53010.72521.18080.7898–1.76530.4179 III vs. I1.40710.7658–2.58520.27121.23520.6366–2.39640.5323Grading 2 vs. 10.70870.4174–1.20320.20230.68820.3973–1.19220.1826 3 vs. 11.03470.5996–1.78550.90261.00860.5719–1.77850.9765Sex Male vs. female1.08430.8562–1.3730.50191.04750.8145–1.34720.7175 Age0.98810.9769–0.99930.0380.98380.9714–0.99640.0116Jaundice Yes vs. no1.42431.1246–1.80390.00331.41861.1013–1.82720.0068R 1 vs. 01.43821.0866–1.90370.01111.35260.9989–1.83150.0508CA 19-9 ≥ 114 vs. < 114 kU/L1.31481.0281–1.68150.02921.28420.9899–1.66610.0596Lymph node-ratio ≥ 0.2 vs. < 0.21.80941.4006–2.3375< 0.00011.66151.264–2.1840.0003T-staging 1 vs. 00.25540.0592–1.10060.0670.12490.0162–0.96220.0458 2 vs. 00.2310.0553–0.96470.04450.12090.0162–0.90340.0395 3 vs. 00.26740.0657–1.08760.06540.12660.0173–0.92630.0418 4 vs. 00.34710.0786–1.53190.16240.13490.0172–1.05610.0564N-staging 1 vs. 01.1580.8836–1.51760.28761.08380.8162–1.43910.5781Pain Yes vs. no0.99290.7804–1.26320.95351.04450.8088–1.34880.7388Pancreatitis Yes vs. no0.95140.7064–1.28150.74310.88580.6426–1.22120.4592Nicotine Yes vs. no1.1060.8705–1.4060.4091.09010.8457–1.40520.5053 Diabetes Yes vs. no1.1360.8545–1.510.381.11070.8214–1.5020.4953Neoadjuvant treatment Yes vs. no1.34490.9616–1.8810.08341.24160.8711–1.76960.2314Stent Yes vs. no1.11750.883–1.41420.35531.16640.9076–1.49890.2291Surgical procedure PPPD Whipple1.07120.7961–1.44140.64971.06910.7808–1.46380.6769 Distal resection0.84980.6152–1.17390.32361.29390.6334–2.64320.4796 Total pancreatectomy1.40920.7425–2.67470.2940.96090.6824–1.3530.8192Localization 2 vs. 10.88280.5386–1.44690.6211.00870.6055–1.68020.9736 3 vs. 10.92890.6605–1.30620.67141.04150.7199–1.50690.829UICC, Union for International Cancer Control; CI, confidence interval; RR, relative risk; Ref., reference; SII, systemic immune-inflammation index; PLR, platelet lymphocyte ratio; NLR, neutrophil lymphocyte ratio; PPPD, pylorus-preserving pancreaticoduodenectomy Furthermore, no statistical significance was found for OS and DFS in univariate Cox proportional hazard regression for neoadjuvant treatment (p = 0.08; RR, 1.35; CI, 95 0.96–1.88; and p = 0.23; RR, 1.24; CI, 95 0.87–1.77; respectively; Table 2). Multivariate Cox-regression analysis using SII as bivariate variable revealed that a high SII (p = 0.016; RR, 0.71; CI, 95% 0.54–0.94), positive resection margin (p = 0.03; RR, 1.46; CI, 95% 1.05–2.03), and a high lymph node-ratio (p < 0.001; RR, 1.77; CI, 95% 1.32–2.36), but not NLR and PLR, are independent risk factors for OS (Table 3). No statistical significant association could be found for SII, NLR, and PLR in the multivariate Cox models for DSF (Table 4).Table 3Multivariate Cox regression analysis estimating the influence of the SII and clinico-pathological parameters on overall survival in patients with ductal adenocarcinoma of the pancreasOverall survivalSIIRRCI (95%)p valueSII ≥ 873 vs. < 8730.71380.5427–0.93880.0159UICC stage II vs. I0.77960.493–1.23290.2871 III vs. I0.94230.4591–1.93440.8714Grading 2 vs. 10.58810.3181–1.08750.0906 3 vs. 10.81040.4285–1.53280.5179Sex Male vs. female0.93280.7155–1.21620.6074 Age0.98740.9749–1.00010.0514Jaundice Yes vs. no1.19940.9094–1.58190.1979 R 1 vs. 01.45611.0457–2.02750.0261CA 19-9 ≥ 114 vs. < 114 kU/L1.16420.8795–1.5410.288Lymph node-ratio ≥ 0.2 vs. < 0.21.76871.3247–2.3615< 0.001UICC, Union for International Cancer Control; CI, confidence interval; RR, relative risk; SII, systemic immune-inflammation indexTable 4Multivariate Cox regression analysis estimating the influence of the SII and clinico-pathological parameters on disease-free survival in patients with ductal adenocarcinoma of the pancreasDisease-free survivalSIIRRCI (95%)p valueSII ≥ 873 vs. < 8730.7870.5885–1.05240.1062UICC stage II vs. I1.08550.6388–1.84460.7617 III vs. I1.08610.495–2.38310.8367Grading 2 vs. 10.52790.2826–0.98610.0451 3 vs. 10.74070.3878–1.41480.3633Sex Male vs. female0.91760.6892–1.22170.5562 Age0.98230.9685–0.99640.0138Jaundice Yes vs. no1.21380.9041–1.62950.1973R 1 vs. 01.4050.984–2.0060.0613CA 19-9 ≥ 114 vs. < 114 kU/L1.13850.8459–1.53230.3921Lymph node-ratio ≥ 0.2 vs. < 0.21.49421.0995–2.03060.0103UICC, Union for International Cancer Control; CI, confidence interval; RR, relative risk; SII, systemic immune-inflammation index

discussion CC BY

Inflammation plays a key role in tumor initiation, malignant conversion, and metastasis and influences the host anti-tumor immunity.3–5 The present study investigated the clinical and prognostic value of preoperative SII, NLR, and PLR in patients with PDAC undergoing resection and competed their predictive accuracy. Overall, SII, but not NLR and PLR was an independent prognostic factor for OS in patients with PDAC undergoing resection. The relationship between tumor and inflammation was first described by Virchow in 1863, and later in 1986 by Dvorak as “Tumors: Wounds that do not heal.” Meanwhile, inflammation is known as one of the hallmarks of cancer.4,24,25 Increasing data shows the close relationship between tumorigenesis, tumor progression, and metastasis.4–6 The major prognostic impact of inflammatory markers can be ascribed to a cytokine-driven immunogenic tumor microenvironment and a significant prognostic role of inflammation-based biomarkers and scores has recently been shown in a number of malignant diseases.5,7,26–28 One of the newly emerging prognostic scores is the SII, based on platelets, neutrophils, and lymphocytes. As a combination of both NLR and PLR, SII firstly has been confirmed as superior prognostic factor in hepatocellular carcinoma and then in small cell lung cancer reflecting patient’s inflammatory status.15,16 In a number of malignancies, including PDAC, an elevated preoperative SII plays a key role in prognosis estimation.12–16,29–31 This is the first study that has proven the prognostic value of the SII and is superior to PLR. It has been proposed that SII is able to predict tumor recurrence in a highly inflammatory tumor microenvironment with infiltrating immune cells that promote tumorigenesis and dissemination.5,32 Neutrophils activate endothelium and parenchymal cells via secretion of soluble factors that enhance tumor cell adhesion at distant sites.33–35 Increasing numbers of blood neutrophils and platelets have been associated with tumor progression and diminished clinical outcome in a number of solid tumors.36,37 Lymphocytes inhibit tumor cell proliferation and migration through induction of cytotoxic cell death and thus play a key role in cancer immuno-surveillance.5 On the basis of these findings, several inflammation-based scores have emerged as prognostic indicators in cancer patients. Recently published data is diverging regarding the prognostic value of NLR and PLR. The NLR, combining circulating neutrophil and lymphocyte counts, and the PLR, combining circulating platelets and lymphocyte counts, has been associated with impaired survival in lung and ovarian cancers, while in PDAC results remain inconsistent.38–42 Whereas Mowbray et al. found preoperative NLR to be an independent prognostic predictor, Chawla et al. reports that neither NLR nor PLR predicts survival in patients who underwent pancreatectomy for PDAC.43,44 A high SII, consisting of high neutrophil and platelet as well as low lymphocyte counts, indicates inflammation activity that may be associated with poor survival through enhanced tumor invasion and metastases. Investigating the prognostic capacity of SII, NLR, and PLR, our results were consistent with those of Chawla et al., revealing that preoperative SII, but not NLR and PLR, is an independent prognostic factor for OS in patients with resectable PDAC.43 Recently, Haldar and Ben-Eliyahu critically discussed the impact of perioperative β-adrenergic blockade and COX2 inhibition on cancer outcomes.45 Thus, patients with resectable PDAC who have elevated preoperative SII might benefit from anti-inflammatory and/or anti-immunotherapy prior and after surgery. Even though the results of the present study demonstrate that the SII is an independent prognostic factor in patients with PDAC undergoing resection, it has several limitations. Although the patients were prospectively entered into a database, a retrospective analysis was performed with a selection bias by the availability of complete blood cell count before surgery in daily practice. The cohort represents the experience of one center that needs to be validated by external cohort from another center. There are no consensual cutoff values for inflammation indices. The majority of studies determine individual cutoff levels by their relevance and significance, showing a significant prediction of survival when applied to the same patients’ cohort. As a result, there is a wide range of cutoff values for these indices. However, the present study demonstrated that the SII provided the strongest survival prediction compared to NLR and PLR in patients with PDAC undergoing surgery. Emphasis should be given to determine significant cutoff levels for inflammatory indices that stay valid when applied to independent cohorts of patients. The administration of different neo-/adjuvant chemotherapy regimens and changing policies of treating patients with borderline disease during the study period may have influenced the study result. However, it reflects the real-world situation and patients included in the study were treated with standard regimens that were available at the respective period. We did not analyze the differences of prognostic strength of SII during different time intervals reflecting variations in neo-/adjuvant chemotherapy regimens. However, we could proof the prognostic value of SII for the entire observation period, regardless neoadjuvant treatment was administered or not. We admit that in order to draw representative conclusions for the association between inflammatory activity and prognosis in patients undergoing neoadjuvant treatment, a cohort with little variations in neoadjuvant regimens should be analyzed. High and low SII was equally distributed in most of the items characterizing the study cohort. However, resection rates, CA19-9 and bilirubin blood concentrations were different between patients with high and low inflammatory activity. The difference of resection rates interesting observation that needs to be addressed by further studies as it may represent an important factor for treatment decision. There is evidence that tumor invasion initiates host inflammatory response and one could argue that the extent of tumor cell infiltration into the mesopancreatic compartment both stimulates inflammatory activity and influences the likelihood of complete resection. Similarly, CA19-9, serves as a surrogate marker of tumor burden and thereby associated with inflammation.

conclusion CC BY

In summary, the present study shows that preoperative SII is an independent predictor of OS in patients with PDAC undergoing pancreatic resection that is superior to NLR and PLR. Measurement of SII is easily applicable and of low cost. Patients with preoperatively elevated SII might benefit from anti-inflammatory and/or anti-immunotherapy.